Track-and-Trace Bill Clears House With New Electronic Labeling Language
This article was originally published in The Pink Sheet Daily
Safeguarding America’s Pharmaceuticals Act passes on suspension calendar, but likely sets up fight with Senate in conference.
You may also be interested in...
Congress likely to release $85 million in drug user fees that were taken out of the agency’s fiscal 2013 appropriations by sequestration, but it won’t boost FDA’s overall budget.
A Johnson & Johnson citizen petition lays out the company’s case for individual non-proprietary names for biologics and each of their biosimilars, citing the risk of inappropriate substitution.
Compounders could submit to inspections, user fees and adverse event reporting, providing potential market advantage; Legislation, which includes track and trace draft bill, avoids compounding controversies and could be poised for swift passage.